CGTX
NASDAQ · Pharmaceuticals
Cognition Therapeutics Inc
$1.07
-0.01 (-0.93%)
Financial Highlights (FY 2025)
Revenue
14.30M
Net Income
4.19M
Gross Margin
30.5%
Profit Margin
29.3%
Rev Growth
-4.2%
D/E Ratio
0.88
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 30.5% | 30.5% | 30.5% |
| Operating Margin | 38.8% | 39.3% | 36.7% |
| Profit Margin | 29.3% | 30.0% | 27.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.30M | 12.78M | 15.45M |
| Gross Profit | 4.36M | 3.89M | 4.71M |
| Operating Income | 5.55M | 5.03M | 5.67M |
| Net Income | 4.19M | 3.83M | 4.28M |
| Gross Margin | 30.5% | 30.5% | 30.5% |
| Operating Margin | 38.8% | 39.3% | 36.7% |
| Profit Margin | 29.3% | 30.0% | 27.7% |
| Rev Growth | -4.2% | +12.1% | -7.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 29.56M | 25.22M | 24.02M |
| Total Equity | 33.74M | 34.09M | 31.08M |
| D/E Ratio | 0.88 | 0.74 | 0.77 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.72M | 5.55M | 6.77M |
| Free Cash Flow | 3.42M | 2.69M | 4.56M |